Physician profile
Anna H Moore
NPI 1063596062
$3,881.76
in general payments reported to CMS, 2019-2025
24 companies · $36.52 in 2025
The $36.52 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $719 · 2023: $1,443 · 2024: $1,043 · 2025: $36.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $631.43 | 2021-2024 | Lifevest |
| Amgen INC. | $598.54 | 2021-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $439.32 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $359.13 | 2021-2024 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $200.33 | 2023 | Arcalyst |
| Pfizer INC. | $199.20 | 2022-2024 | |
| Abbott Laboratories | $162.93 | 2021-2025 | Ensite, Viewmate |
| Actelion Pharmaceuticals US, INC. | $160.04 | 2023-2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $141.85 | 2023-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.28 | 2022-2024 | Jardiance |
| Boston Scientific Corporation | $127.23 | 2023-2024 | Watchman Access System, Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $121.87 | 2023 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $117.28 | 2023-2024 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $111.77 | 2024 | Arcalyst |
| Abiomed | $55.91 | 2023 | Impella |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $52.83 | 2023 | Injectafer |
| Inspire Medical Systems, INC. | $47.91 | 2024 | Inspire |
| Amarin Pharma, INC. | $39.23 | 2022 | |
| Esperion Therapeutics, INC. | $38.12 | 2021 | |
| Alnylam Pharmaceuticals INC. | $37.47 | 2022-2023 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $34.50 | 2024 | |
| Philips North America LLC | $29.40 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $26.07 | 2023-2024 | Wainua, Farxiga |
| Merck Sharp & Dohme LLC | $18.12 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.